Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. And welcome to the BioAtla Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen only mode. [Operator Instructions] Please note this conference is being recorded.

I’ll now turn the conference over to your host, Bruce Mackle.

begin. may You

Bruce Mackle

business following and Medical Q&A. the joining update operator Chairman, everyone. Earlier and me Operations; Officer. ended With and Strategy is of Martin, Thank Commercial Development the website. and Clinical from Rick and good Sheri company’s BioAtla on and And Financial Chief phone President, results Richard quarter Sievers, Jay and the press the will financial for Short, call, be a afternoon, are fourth today full this December a Philippe Co-Founder; A Vice Chief Chief you, BioAtla Eric XX, Waldron, afternoon, today’s release released Officer Dr. CEO short Senior copy on Jay for year Lydick, available XXXX. of

subsequent Form expected reports about with and the various recent the G&A submissions, are results and on to differ expectations and our begin, licensing and I’d made meetings whether clinical future including, forward-looking Form in can include progress sufficiency our quarterly made BioAtla’s business programs prospects, remind annual the trials, call everyone plans XX-K in path regarding are and equivalents clinical to, R&D development candidates; regarding to partnerships, described statements, conference registrational, XX-Q. the the statements most regulatory clinical actual research this that like filings product of updates, and respect statements collaborations that and regulatory and during other selective and our including Before cause and timing and results, for to assumptions strategic statements trials, conduct, potential will regulatory expenses. but our uncertainties report limited be on not and our we approval trials SEC, expectations enrollment risks, subject and of with cash plans to These materially dosing clinical data trials; potentially will potential cash

place disclaims undue March forward-looking future statements, required to BioAtla speak of such not cautioned only obligation circumstances, events information, reliance statements as reflect these except any update which are You and today, by law. as to XXXX, or on XX, to

like I’d Jay? turn over Short. to Jay that, With call to the

Jay Short

for fourth full types. Bruce. BAXXXX BioAtla made for latest And significant trials thanks quarter call. us in our Phase multiple joining CAB-ADC and BioAtla BAXXXX our earnings for and year five two to X Thank everyone candidates product solid progress our XXXX XXXX across tumor stage first-in-class ongoing you, targeting has

and the EpCAM clinical the bispecific CTLA-X, types, in antibody continue IO engager. first T applicability and advancing and We our of several across focus our naked RORX CAB ADC our leveraging AXL platform, including further trajectory CAB preclinical innovative positive programs dual of stage on development across and clinical cell broad XXXX, intently technology antibody, our targeted the CDX

the remind company providing to present like our I'm additional to on updated that what helpful update, our Before website going to everyone you. are part I'd of that as be to details may related presentation available

exceeding cases, clinical the meeting several We target responses are are to that and, interim our by generally promising date in study excited responses.

data studies these from mature completion term to sets release going recognize forward, we near plan the updates providing more the our resulting of sample year incremental across impact view In of small programs. However, we sizes. on data

to registrational studies company's potentially X, these for our likelihood As data set the provide success parameters using we to of us are maximize a reminder, that sufficient study to studies. allow Phase

platform tumors. be that do of communication not the updates for will delay I anticipate QX, in program modestly while timelines our treatment advance we a While this affect what development solid the will will this overall data we transformational approach believe

maximize the on of throughout set doses to as X data now Phase and leading well X. dose CAB-ADC, from for beginning our risk order as of thorough a regimen regimens different of benefit XXXX, Phase Phase the the part for Let's updates to differentiated progress part to and profile a dosing move at and financial operational we've Two Based year. response we've our our clinical, the looked the more study. able accumulated; X selection exposure frequent analysis sizable to our intensive we complete UPS X In were

approximately or twice three are times intensity X.X previous regimen. profile XQXW X.X four respectively cycle of the and weeks regimens and week frequent a mg/kg the the dose uses at mg/kg to the the dosing XX% or regimen week two the provide While QXW XX% more mg/kg three exposure, dosing more which in expected dose mg/kg a in once or positive, than is X.X X.X starting every QXW cycle, the QXW

response BAXXXX for we X non-small cell shared study. the related BAXXXX cancer Phase Today, X providing additional intensive exposure indications. our dose learnings on across partial intensive our the Previously, are our we or multiple anticipate interim the profiles dose analysis, anti-tumor having and data these RORX that strategy as Phase more on compared response more further including by will regimens improve applying regimen. was This to activity Based even supported dose analyses, ADC more dosing design from part X safety of our BAXXXX with study our interactions study regimens our frequent, similar things, be FDA improved and of about QXW and assets how is exposure alignment part frequent lung Phase Optimus. and lead AXL-ADC these to X part UPS Project encouraging the insights, of broadly discussions FDA's two view as part as FDA safety sarcoma continue first BA In well data the we study programs. our our are X excited with we while in X UPS we

UPS XX% with sarcoma specifically BAXXXX the no soft one study our one nearly tend is First, on of I to registration focused representing with Phase differentiated a approved year of FDA highest one the the and continued recurrence most subtypes moving are treatments patients aggressive significant sarcomas. progress continued a rapidly. treat strategy. There It all UPS. our will largest is by of currently of a discuss sarcoma to and Last overall subtypes, Thus, and lack of sarcoma tissue X and UPS as standalone execution also activity, anti-tumor results UPS, we was progression BAXXXX UPS. disease strong profile safety of very promising quickly opportunity are represents to commercial rates. marked indication, in in

we safety update medium to response from currently the FDA encouraging a with progression initiated we XX-months of study X X, Based of UPS feedback differentiated around response As trial. profile duration and an or the of months. survival the part eight an potentially X of or exceeding see and XX%, on the results Phase ORR PFS study, rate objective overall the these portion together the part registrational free continued design, of

between Phase are will in regimens. first than the a Phase This be this half anticipate period part TMPs randomized to soon Xst to X, one enrolling now of the and month, the patients dosing to for first dosing X equal trial. UPS these DLT patient the study greater Leiomyosarcoma of of XQXW using XQXW the study was six in this XX% now patients requirement XX a in or first year, one with observation XQXW or the patients part study which X We X cleared in enrolling begin

selected primary plan Following enroll study. patients at an selected approximately the the endpoint on complete Overall, dose based treated ORR the additional XX efficacy regimen. will XX at to to this, patients the we be dosing

we subtypes, liposarcoma, soft In where and XX% synovial across continue activity sarcoma previously to osteosarcoma. at reported PFS of in rate in UPS, XX% several addition to bone and tissue XX we in see sarcoma XX% observed antitumor an positive weeks

We Phase encouraged X part advance our meet study. continue of the that go are all criteria to very to X subtypes three into predefined

six frequent and in to period are We recently sarcoma intensity patients regimen, patients continuing the respect With broad tissue also subtypes. earlier, study opening to up XX in XQXW enroll study to the a dosing for continue Leiomyosarcoma, X soft Leiomyosarcoma Phase for the mentioned I this XX future. in potentially using the the more regimen evaluate to this observation sarcoma dose cleared DLT remaining we first

With regards observed in X a the to profile with across to with continues consistent the Phase subtypes, profile safety sarcoma Phase X. well we tolerated profile be generally BAXXXX safety

activity we’re UPS observing, We a represents coupled company. stage commercial solid with BioAtla. a encouraging transition indication unmet need, significant early that antitumor for a the plan into Given for the

up We BAXXXX also Ultimately, unmet in over our value area, footprint real the has billion over in generate this a $X revenue subtypes. XX,XXX expanding high in see treat to time potentially per sarcoma and very need. other sarcoma year to to sarcoma patients worldwide potential include

who patients treatments responses are onsetting. of cell we're Regarding second refractory study lung the AXL inhibitors, limited line and our in Phase BAXXXX progress, available to XX%. by have checkpoint be overall cancer, are multi enthusiastic XX% positive There observing. the the options non-small approximately suboptimal treatment not of immune we for continue to patients in These ORR X

in As of response inhibitors. an this is failure with PDL-X, previously Phase cancer competitive potentially observed efficacy to is of either Phase moving study. the this highly study. a or study PD-, reminder, previously ongoing experienced non-small of cell preliminary The X positive of lung X in who part patients actual have EGFR ALK a was PD-X X, population ORR registrational of in This of failure forward part approximately XX% supportive rate the and so XX% far to reported

lung the well BAXXXX will current dose our part be observations, and commercially interim discussions observed non-small above multi with to Phase patient X, in more preliminary intensive XQXW X the frequent and ORR ORR regimens FDA refractory cell leveraging we on include population. believe highly Based UPS, XQXW. a an on we study insights our Further expanded cancer relevant

complete, part meeting the registrational initiate half cancer enrolling the data complete cancer all submission cell in expect this year, overall X, the the year, potentially We feedback is anticipated non-small Phase second we of is X effectively the of the We timeline also that study cell non-small anticipated to half anticipate will of registrational our we we these this dose Phase development our half a importantly, of design the in prepare with in half, confirm the of patients study with second indication. of preserving after second first reporting as which these Most request are the lung the XXXX. part lung in selection. currently for agency in with X, potentially for final the X

patients per a that size, worldwide line of significant at second in lung approximately has year revenue XXX,XXX market billion AXL to estimate billion and peak. the $X positive to addressable respect worldwide. there add are cancer non-small AXL, over proportion plus cell to indication express With This potential we $X.X patients

best-in-class non-small treatment across types. of tumor solid a has to multiple that thus Of BAXXXX significant even asset commercial fail together multiple Taken medical significant importance we believe BioAtla BAXXXX lines for filling cancer, has a cell potential of sarcoma need. greater unmet become the is number potential and who significant therapy, to lung the patients for be a

multicenter To are round we supporting X BAXXXX in BAXXXX, out platinum resistant CAB-ADC trial, ongoing our ovarian Phase clinical investigator initiated patients cancer. an with program,

this consisting We data are patients anticipating second of in year. interim the half XX of

Now BAXXXX, candidate ADC. turning product a second lead CAB-ADC CAB-RORX to our

As we have trials three we a clinic, no other treatment RORX the a have the tumors. BAXXXX. to first-in-class in Phase reminder, have X targeting with there date, for therapies solid ongoing potential so are To

including who cancer, have previously response tumors, to in Phase in remission complete XQXW more frequent, and this and patient patients on positive and cell the for head we PD-X clinical patients over lung cell responses more we non-small plan in positive therapy, remains enrolling two RORX non-small PRs treatment RORX cancer first potentially actual saw study. cancer strategy of the in one half years. similar Phase evidence in reported regimen in year when a intensive proceed share our determine to PR our we two off refractory data dosing done same registrational As in exposure of complete a lung data, how with are response our impressive melanoma study the analysis pursuing Based to in and currently X in neck in X sufficient to one positive

earnings biopsy patients in first in invaluable an identified in providing of who and therapy we additional Regarding enrollment screening anticipate XXXX previously CR the experienced a with the failure following are patients or an Melanoma quarter an the around our validated have update trial X liquid May. Phase PD-X validated on call IHCSA, using patient

in neck is In and have failure patients addition, alone head study who or PD-X Phase our experienced platinum ongoing therapy. previously X of with in therapy combination

XXXX on this achieved earnings first have call study line or We providing for RORX in is high, the quarter our around first expectations, enrollment positivity update so the far, patient an and rate in we observed anticipate with in May.

program, multicenter in To clinical our of initiated with cancer. CAB trial are X resistant a Phase out we ovarian CAB-ADC platinum patients BAXXXX round BAXXXX supporting investigator

data are this year. in patients consisting anticipating of half interim We the XX of second

our CAB-CTLA-X as be in Now the tumors to will progressing conducted trial evaluate safety Phase to Phase I'd and with being in and is planned. like is The for BAXXXX briefly X/X trial about responsive talk antibody known trial X/X CTLA-X in BAXXXX. combination to tolerability and monotherapy nivolumab, of treatment

As that the for combination nivolumab. were reported. to I'm pleased mgs/kg cleared of at the DLTs DLT mg share period part update, three fourth No XXX of dose today's cohort of in or observation a with Xmg/kg was

in are in year. mg/kg second in monotherapy Xth as nivolumab a X the with Phase data of anticipate mg Plan readout We half or to cohort and the this now progressing XXX mg/kg X at the or combination X

Several for in pipeline T-cell FDA potentially on candidates, stage and We recently also we in demonstrating the or to next. that IND therapeutic IND combined our of three enabling patient the track product holds submissions of CAB-EpCAM potentially clearance XXX our lung, the of unmet to and earlier our CAB through of potentially promise for index and this adenocarcinoma antibody BioAtla include tremendous data to IND breast, additional progress CAB-CDX in bispecific of year. CAB need are this improvement non-CAB antibody, continues treatment the this advanced have half several subtypes adenocarcinoma the namely, vivo our still Phase much colon, CAB an to for can and CAB complete year, X to next prostate. studies engager and preclinical on next in view common other Phase of X first-in-class anticipated most Similar received first the in due variants for pancreas including we candidates year ADC address the candidates, studies, readout the over bispecific anticipate and antibodies, generation dual the first dual BAXXXX. with design. relative selectivity the clinical the that study fold Moving of

With respect ESMO, including which and poster presentations, European Lung of Congress, recent the has Congress, related Sarcoma to company and data Rare to ADC and the important include ongoing will the in accepted Cancers next seven generation and bispecific. Cancer upcoming communications, AACR, preclinical latter multiple

Rick quarter like now to call year that, turn to XXXX fourth full review With the the I Rick? would over to and financials.

Richard Waldron

Jay. you, Thank

of XXXX, cash had As XX, equivalents, million we and $XXX.X compared December in as $XXX cash million XXXX. to XX, December of

programs, including We expect current cash ongoing development and cash equivalents will be sufficient to CAB fund all and planned XXXX. operations, into product

control As and the a product reminder, CAB market rights we in Japan. all US, Europe

stockholders. Our value extend other for opportunities in global create royalties generating upfront in or selective approval provide and licensing commercialization milestones by with cash key includes certain collaborations while and to also business territories commercial markets that upon advancing the additional to product of through runway preparations our and biopharmaceutical could development regulatory exploring companies us strategy rights cash

million year the net a $XX.X were loss the a $XX.X loss to million reported development XXXX, full of same of and same December driven ended Research for For year-over-year was $XX.X XXXX. in the net by year million million $XXX.X compared expenses XX, of the we in of product compared to our full XX, period XXXX, efforts. for XXXX. clinical December development ended The million period increase $XX.X primarily

$XX.X XX, $XX.X the million decrease XXXX. to was million in XXXX, $X.X from XXXX change for variable candidates General in period. period expenses stock-based quarter-to- activities programs. a ended R&D increase administrative compared our same to attributable advance quarter our December compensation as million to and for for remain expect in year R&D the to expenses generally we continue our The We product the were invest and clinical and to

G&A to our for a our advance BAXXXX expect activities requirements candidate moderately satisfy portfolio, intellectual development company. support product We our support property as increase expenses to of product public our pre-commercialization candidates, focused and

compared XXXX in $XX.X was in in Net the for used of ended XXXX is to an And million to XX-months and development the cash XX-months used back compared in same December in to operating development XXXX. increase $XX.X net our cash activities program The operating XX, efforts in XXXX. increase the net operating million of period cash due activities activities primarily for related now expenses as to to Jay. XX-months the for used research of

Jay Short

Rick. Thank you,

we made are our with have progress cumulative that and in the proprietary the We results both pleased support preliminary to and platform. XXXX efficacy CAB from differentiated our continue safety

treatment X Phase more intensive clinical providing robust more become emerge of compelling cell and the continue with to data regimens excited non-small when updates sets in the available. clinical the advancing is UPS beginning lung eager dose addition studies are and We that cancer frequent are with refractory and to profile

execution We in months. poised to promising reach encouraged also key remain several milestones of cancer are CAB the our by several and assets the value and creating other indications well continued and points multiple next inflection

of confident have the remains our the patients and indications of need will shareholders significant feel for BioAtla high worldwide. unmet impact about we medical that with future, pursuing goal

With that, we the back operator to will turn your it take questions. to

Operator

Instructions] [Operator

question first line from of with Brian Cheng JPMorgan. Our comes the

Brian Cheng

team, non-small my program couple on piece. AXL especially and for lung question just taking first cancer thanks questions. today. your Jay Hey, A Maybe the cell in and of

trial so you intend on you Can design? thinking are just your provide thinking color patients trial latest What the pivotal your one And the about to some design. mix maybe about latest the on enroll? pivotal that

study? a your And waiting point pivotal ESMO time ups. is for more of the potentially ongoing lung come your follow then and gating have your cancer updates you're start cell you. the that one are any FDA, then from that could couple any that is feedback between up secondly, And for non-small Thank expecting now for we factor I And trial.

Jay Short

Brian. Hey. Thanks,

speak, with preparing as intend part X, to discussion, the for from treatment with put analysis. the feedback take Phase part this factor from we realized could factor later intense dose learnings and nice in a to we able increasing exposure together, timeframe discussions, that and X. that discussions in that discussing working the we so So this in third first same UPS more be request could FDA the bring half. the have do to that feedback about gating in patients, this we a with We for was is we quarter that in a Obviously, are that thorough frequent response FDA our the and were also timeframe from FDA. of is we're we gating our that'll in more those What number

So the when question about do completed, answer the that also very readout, and get next we an compare only about, dosing. the that have the the opportunity XQXW you not have step to more the back to and we think is what's feel positive the we which QXW after because now data best FDA to dosing but we'll feedback, we XQXW will time frequent

And make registrational chance course, that. so a that we're it's registrational really And the do sure the going allow to this portion FDA of gives to us us that the of will into trial.

get some to the sure But maximized we it. that's feedback is So of success. yet. we've that's And looking our for need to potential how make we're our at job

Brian, for you on and that and good we we'll it. I if a these little the think gives don't have with be upside with other answers but we comparing them. a So we your doses, question, hopefully flavor baseline QXW, chance a have know

Brian Cheng

I side, any on non- Yes, cell then couple we're RORX shed cancer that curious saw can patients don't you small dose what on you the maybe the if very lung can work initial on saw cell And with you lung the was in one you that the on light some are in doing know profile cancer, to piece. just of the light AXL helpful. you AXL cancer in with how program shed that already that you program? saw. just compared lung given you RORX the the non-small efficacy some efficacy what And

Jay Short

call. QX yet. We have were the our targeting earnings is we clear, QX for which, only Originally, Well, call, enough patients don't X. to to out earnings do we can be just report that on this Phase

timeline of we earnings the in have dose in milestone call So done opportunity one intensive fact But comparison, is information more reporting make but we it given the we've frequent pushed out the QXW. the May. of dosing that side terms what between or our the comparison timeline a the pivotal bring X Phase and to QX overall allows that doesn't in the is frequent, that's in terms all, more it, now in these at us actually change to

make have for is get to required course, So to today wait I but we into goal picture of have better we to RORX And to that. much second don't information a think as the our the have picture a a FDA half. of and enough data comment, go back the we'll

better We of head also hoping a to assay in what's course, a should And circulating melanoma. the have, our snapshot hopefully neck. the happening is of in of recruitment tumor but we're going May, and picture cell to rate then and update we'll what we're much have get on

Brian Cheng

Great, my for Thanks taking thank question. you.

Jay Short

By the way, thing. Brian, just one

We submitted of conferences. one have upcoming to to the

meeting, the We analysis data so on yet but regimens. response more from get get as feedback we hood intense intend possible can soon people a the to other frequent, under and flavor these as present dose the haven't exposure got

Brian Cheng

For the RORX.

Jay Short

AXL. RORX and For

Operator

Shi the Jefferies. of next from line Our question Kelly with comes

Kelly Shi

first is UPS. question for in you My questions. taking AXL program about my Thank

the the talking a XX LMS XQXW X, curious, and I'm first X, XX and patients been dosing different would after curious, part dosing, patients for for cleared at Phase you in safety XX the next I'm decision and frequent efficacy another two in near patients you. X? Thank for these regimen part does dosing, a meeting require window on term mentioned and for You patients efficacy the FDA patients. about more XQXW, has the you're also in first the to DLT share six evaluate going for the XQXW.The outcome in subtype. six

Brian Cheng

scan when in scan. we the this on start did I'm Leiomyosarcoma Philly we January me on the of reported one out first at let Charlie. by you, reduction going Thank saw that to in the saying help a first but XX.X% tumor XQXW little going snapshot I'm patients get of to of one you bit,

So XX patient. we they'll XX fashion some we patients, But coming come going we this get going until are and to just we're to first that the because of that out we believe timely data maybe we're in to wait this in that. was see those moving toward a add obviously, very interesting of answer. half But year. we're for that But second you hopeful to can Philly, think

Philippe Martin

is XX first intention patients, to we the that dose next them align the to to score, for Yes. With the year, selecting about to with our that's for meet and as we dose to will sure then regard be patients with the are is ask after that we FDA we'll wait us but And Jay which XX the until be not data, approximately meet FDA make your enrolled, registered. have XQXW this timelines expected LMS require half on XX patient because of to of them worth second certainly question the be mentioned. in does requirement. we

planning And so have meeting we'll the having a be we first agency patient in XX once on UPS. enrolled with the

Kelly Shi

very have if a up, you may. follow Okay, also I thank much. I

UPS So activated? have year? do any And to able moment, information to be Phase been this regarding at you the updating would provide also sites you many the how share for the X, data plan

Jay Short

you Philip, if –

Philippe Martin

from last the the update all this we we've in to reported provided time just has we data evolved date. the the patient treated the data UPS on median The so is data. PFS Yes,

we XX date months I like we time were now at last months, something at reported about and think the which that. are We X.X approximately

is So the positively. PFS evolving

UPS. But other question? the data your treatment, Some reporting you today on patients sorry. I I'm a are that in still might close we final are continue is think basically, very to got so was the to evolve. data What very

Kelly Shi

Yes, moment, trial. many so plan at X, study to I data have year? been Phase And have the update activated, sites potentially how this pivotal site? meant for the another the Do you

Philippe Martin

we have Patients data anticipate This update. registration being to randomized. I is are study. a don't believe

good what tissue enrollment update, were leverage planning bone sarcoma will the provide was initiated we certainly And So UPS, we're is Phase data giving for X. we sites not with but part and all on all for study this soft the X, had sarcoma able updates. that to

are the Hong altogether this about sites sites to these US, Kong being the and So which Taiwan. in phase, part XX transitioned second is of

Operator

question of comes EF the line Tony next Our Hutton. from of Buter

Tony Buter

thanks much. very Yes,

for a So and the around anticipate variety would of dosing there's one in a clintrials.gov, question been tumors. clearly CTLA-X program

So or have one patients particular all at dose program, enrollment efficacy? And has simply much. in same within but it you enunciate can be been that been entire first actually start clintrials.gov that schedule? it your is, importantly, are in which been, that's DLT? you, this then could Do for? question an has has That's of do if have tumors the what it Thanks to simply it the half? early is Is that included skewed you're looking first and then very you just the dosing on Will the dosed appropriate takes you when fine, question parameters number looking think and that you not, think year? another? the which listed And tumor one, two will get to

Jay Short

Philly. with you're this that I split in combination But you're to when at an in when dose going X X with mg/kg, especially race, think I'm so mg/kg approved PD-X.

cohort. that passed We mg/kg we So passed X with just PD-X. the in of mg/kg X combination

combination efficacy the in cohort So another Xmg/kg X that's range. mg/kg PD-X. for there's We're enrolling now with in that

with this in But have that. in our the off BAXXXX initiate everything so the on course, I I we So of is Phase will track on times we look cohorts kick to the efficacy, think be X the actually study done out two for general, in or can last think, and potential at at trial looking CTLA-X. that in such

about see questions very for data So far. good efficacy a coming it's way pace, tumor be two maybe answer. in is other comment But were it maybe even the and there on some Philip we and hoped regarding the the thrilled better and so to that or would types to a forth would we're readouts so

Philippe Martin

Jay. Thanks, Yes.

the All our we have tumor tumor is only I been listed. activity tumor other type of quite patients bit have all bit So we that of quite the coming and types enrolled. HCC have to not in seeing We're a the point. enrolled this think at a types study

Jay nivolumab indication, as so, X were nivolumab mentioned, mg combination is surpassed X really efficacy mg/kg other And indications. in that we've in X mg Ipilimumab at mg/kg at plus certain expected, threshold Ipilimumab approved levels with X we

level also so as dose such but the markers part reached looking with us X burden, efficacy, forward we'll where study. we to which the help CTDNA, to on at efficacy, So have cohorts also Phase we expect a and tumor decision of make other on to certainly these take be forth, into see so of

Operator

next question Wainwright. comes with of from Arthur the Our He line H.C.

Arthur He

Hey. Good for Thanks and Jay Team. afternoon, my question. taking

up program. follow just CTLA-X So the on

in how you little the give could of have dosing the on average reached? a So far study color been so repeating dosing XXXX of far of maximum about and us study, bit your the repeated

Philippe Martin

is to been really to we're I quite Yes, XX got quite and we have on the going starting doses at only report. specific one each that look to to to mean patients long cohorts, treatment is standpoint. time we But to drug some patients that but stay or how report We've the much cohort. is well very so treatment tell to safety with treatment But some really so stay patients. at so can are be above in is able efficacy that But exactly on again SEA nothing unrelated to doses see you what no treatment. plus approved a able is and these at of are was are with ipi and far on far, far, even nivo, on patients DLT from the time need drug read we've by one cycles. cohort had there's in get the say what for was more tolerated, had we time not early the individually so to able far, Again,

Arthur He

the curious. what's Just more And curious for cohort? go regimen the rationale sarcoma? Why the Thanks I'm regarding LMS testing program subtype not dose of AXL just study, in of for sarcoma the part the and frequent the Great. the the for color. other to intensive

Jay Short

mentioning these those actually like we're which that dosing, with the the worth associated it but more the it's and to were on is more XQXW that any often increasing follow I also dosing, frequent Cmax, Cmax think. Well, first intense lowering Cmin, actually, Cmin. toxicity, off, from

exciting. is a from modeling standpoint, this So very

you is, side at Phase study X of and other QXW data, myosarcoma, saw when our we Phase the think, came those in So where we some look I XQXW. in the it X PRs back used of the line and

using was the didn't Phase So PR what in QXW. interesting X was kind a of see the we

quickly. we was FDA And this indication into by went LMS, certainly question answer could felt agnostic, going so we the safety the to. which we in And

in to it So could broad expansion future, it gave chance could a look sarcoma tease And study. LMS if a safety at the a PRS, also up open out the which answers really broad us to tissue see we also soft question. potential

potentially registrational Phase So part X, part in course, the have kind of you our for two wouldn't our first birds six stone, those X portion study. of kill one counted of and UPS of

of way very so optimize delaying bunch without UPS to the just And was it potentially a in a whole registrational study. really any way quickly questions

Operator

with line Benjamin from comes next question the Reni Securities. JMP of Our

Reni Benjamin

Hey, guys, a bit dosing talk a what about I see you before to forward with declaring taking regimens, thanks the frequent you'd for little just like the go can guess dose? sticking questions. more

responses? it how don't study? you meaningful will that do And hurdle, perspective to just appropriate you you ORR dose see primarily or the is safety into kind of or your doesn't I something the improvements if dose? from going that, Are to choose that looking forward of Or for registrational lead course forward go anything a in declare you guess just related deeper meet

Jay Short

add use to of the So I'm freedom Philly But recognize have even it's intense reason on first, is it. and the important the technology. start to this regimen we to this in let and to going because added one CAB frequent, more dose

to So we're different these and XQXW the regimens, be QXW, not all three all to does we're That's exploring. of safe. expecting QXW question

FDA the CAB of free us And supportive UPS do study. In extremely it. was that fact, allow the that to

and is seeing Our we're reason even greater QXW. it have efficacy, for chance efficacy drive we're the a happy with to exploring on we potentially

in have it development So great timelines, a extend UPS and the increase in it Phase of don't that But X not way setting, misinterpret that. your X the did a do you And can we opportunity the chance that. overall part was a inside does do study. to to if efficacy you it

actual the in in do lung, in Fortunately, able for it the setting X. we're RORX to part

delay behind in responses. potentially time has chance done getting same and while least more has to likewise six and that at even we're the stronger effect for AXL, see we're So and efficacy it on it so months FDA, been in it, no the always and process, us a AXL, gives or with having discussions so the really RORX

want to So, Philly, that? to do add you

Philippe Martin

first or with which fine. Yes, I add or XQXW same work meet the your And to does do our to just dosing if that's the meets regimen. as what criteria, doesn't the is or it, the seen you mean about of which part one doesn't we've other question,

point and XQXW and to with are it. We efficacy just we'll we We're the to select get platform. That's can with the the XQXW the CAB at move other It's we and have for the the time not forward have forward. trying work in leverage happy regimen, that that move and dosing maximize us QXW dose. to a

Reni Benjamin

Got it.

two guess. other I questions, Just

the non-small responded can patients or first, study, us responding you lung let the non-small still know are just The cancer, are lung in now? cell cell comment they who cancer in

Philippe Martin

do Jay, take you want to that?

Jay Short

take you that one. think I should

Philippe Martin

you the patients can that tell we responding. Yes. I not of Yes. some decided update have the still but I are to data, mean,

Reni Benjamin

on a to some with where look switching dosing, I'd this be how standard standard guess, at what's titration I just I gears therapeutic to ideal the, these EpCAM commentary of then a point you it for just guess some of kind what's And the me how love kind you or dose with to the to asset. think these, get timing. might I clinical the Excellent. and then or get titration and feedback trial titrations help the as complicated I bispecific, guess seems design,

Jay Short

XX can that's into XXX but mg/kg, this EC that and add I'll group might the around you in but efficacy see you the Philly, start Yes, A level. below we're thinking that

think our preclinical think above we but it could go studies profile that that's given we see you really that to safety a things. and So level Obviously, could dose some our start the Philip, is also logic group could see you Maybe that. to around the in with to the wanting of B you FDA respect some can what add titration. additional to add some

Philippe Martin

so is so Yes, so concerned release is about for T some FDA design set make but it a engager. been to we're not hasn't patients and cell this all with have bispecific many is risk. that all There been that The is to try mitigate CDX cytokine at a typical particularly far observed bispecific and it CDX up sure that other storm this atypical. putting

even we have have reactions grade were seen talk have to see any or but our two infusion case seen design release type not to cytokine of that follow We we neither study during neurotoxicity we and still syndrome. above in

So all that. The per accelerated fast. patient one observation titration It is days that's XX done phase period. is DLT really is it to manage cohort a

low begin we so trying is drugs that titration those not is is that we're what believe tell a dose more are So this relatively efficacious. I'm at we that quickly that will it all levels But go a potent why through standard to not, with. at atypical, and to into then be of you. of move These can extremely starting and is

Operator

the turn remarks. over Short back to closing we Jay call the And question reached and answer end of the have now session. I'll for

Jay Short

their with and speaking thank least Well, time May look our want again, in forward I the And thank to also you you. quarterly we to today next earnings BioAtla with call. at Thank team. everyone for

Operator

And at Thank your And this for today's participation. your you conference. lines concludes time. may this you disconnect

BioAtla (BCAB) 23 Mar 232022 Q4 Earnings call transcript